Mark G. Lewis Appointed New CEO at BIOQUAL After John C. Landon Retires

Mark G. Lewis Appointed New CEO at BIOQUAL After John C. Landon Retires

 

BIOQUAL Announces the Retirement of John C. Landon as Chief Executive Officer of BIOQUAL and the Appointment of Mark G. Lewis, BIOQUAL's President, as Chief Executive Officer

ROCKVILLE, Md.--(BUSINESS WIRE)-- Dr. John C. Landon founded BIOQUAL in 1982. He led BIOQUAL for more than 30 years as President and Chief Executive Officer, and grew BIOQUAL to its current position as a $20M+ life sciences corporation.
Effective June 3, 2013, Dr. Mark G. Lewis, BIOQUAL's President, was also appointed to succeed Dr. Landon as BIOQUAL's CEO. BIOQUAL's Board of Directors had appointed Dr. Lewis as BIOQUAL's President on November 15, 2010, based in part on the belief that Dr. Lewis would be a strong candidate as a successor CEO. Dr. Landon will also retire as an employee of BIOQUAL on August 14, 2013, but will continue as Chairman of the BIOQUAL Board of Directors.

Dr. Lewis joined BIOQUAL as Senior Scientist in August 2003. He became the Executive Vice President in October 2008, and served in that capacity until he became President in 2010.

Dr. Lewis, 58, received his B.A. (1977) degree from Ohio Wesleyan University and his Masters (1980) and Ph.D. (1983) degrees from Ohio State University, Department of Veterinary Pathology. He performed his post-doctoral studies (1983-1984) in the OSU Department of Pharmacology, and continued at OSU as a Research Associate until 1988. From 1988-1991, he was a Staff Virologist at the Southern Research Institute, Frederick, Maryland. From 1991 to 1998, he was a Principal Scientist for the Henry M. Jackson Foundation, Rockville, Maryland. In 1999, Dr. Lewis rejoined the Southern Research Institute as a Staff Scientist, and in 2002 was appointed Acting Director, Senior Scientist.

Since joining BIOQUAL in 2003, Dr. Lewis has been the primary factor in BIOQUAL's growth in the area of viral infectious diseases and has attracted to BIOQUAL several new commercial and government clients.

Contact:

BIOQUAL

Mark G. Lewis, Ph.D., CEO

301-251-2801

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.

The RNAi therapy drove a 72% reduction in urinary oxalate from baseline, boosting Alnylam’s hopes of using the drug in a broad patient population.